Puneet Panda, MD
Ophthalmology · Marietta, GANPI 1073827895
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $156,559 of the $185,246 with a category attached, or 84.5%. Sun Pharmaceutical Industries Inc. accounts for 87.5% of it on its own, with 21 other manufacturers making up the rest. Among ophthalmology clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 428 payments — averaging $432.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sun Pharmaceutical Industries Inc.$162K
- Oyster Point Pharma, Inc.$19K
- Harrow Eye, LLC$829
- Kala Pharmaceuticals, Inc.$410
- AbbVie$392
- Alcon$348
- plus $2K from 16 others
What the payments were for
- Speaking & faculty fees$156,55985%
- Travel & lodging$16,3049%
- Food & beverage$12,3837%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sun Pharmaceutical Industries Inc. | 252 | $161,998 |
| Oyster Point Pharma, Inc. | 30 | $19,328 |
| Harrow Eye, LLC | 21 | $829 |
| Kala Pharmaceuticals, Inc. | 18 | $410 |
| AbbVie(2 entities) | 18 | $392 |
| Alcon | 13 | $348 |
| Tarsus Pharmaceuticals, Inc. | 17 | $318 |
| NEW World Medical,inc. | 3 | $267 |
| Dompe US, Inc. | 12 | $265 |
| Thea Pharma Inc. | 8 | $222 |
| Bausch & Lomb Americas Inc. | 10 | $215 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 8 | $174 |
| Biotissue Holdings Inc. | 7 | $134 |
| Glaukos Corporation | 1 | $128 |
| Rxsight Inc | 2 | $59 |
| Novartis | 2 | $41 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $30 |
| Eyevance Pharmaceuticals LLC | 1 | $24 |
| Sight Sciences, Inc. | 1 | $18 |
| Amgen | 1 | $17 |
| Alcon Research LLC | 1 | $15 |
| Quidel Corporation | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$185,246 in reported general payments places this provider in the 95th percentile of 481 ophthalmology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CequaCyclosporine | 254 | $235,994 |
| RestasisCyclosporine | 115 | $119,368 |
| TyrvayaVarenicline Tartrate | 141 | $101,423 |
| XdemvyLotilaner | 29 | $54,140 |
| VevyeCyclosporine | 35 | $30,092 |
| IlevroNepafenac | 74 | $27,865 |
| BesivanceBesifloxacin Hcl | 84 | $18,580 |
| Cyclosporine | 43 | $17,731 |
| LumiganBimatoprost | 25 | $16,148 |
| ProlensaBromfenac Sodium | 32 | $11,593 |
| InveltysLoteprednol Etabonate | 37 | $10,766 |
| EysuvisLoteprednol Etabonate | 22 | $10,602 |
| BromsiteBromfenac Sodium | 32 | $8,660 |
| Prednisolone Acetate | 207 | $7,250 |
| Bromfenac Sodium | 41 | $6,046 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sun Pharmaceutical Industries Inc.Cequa, Bromsite | $161,998 | $244,654286 claims |
| AbbVieRestasis, Lumigan | $392 | $135,516140 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $19,328 | $101,423141 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $318 | $54,14029 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCBesivance, Prolensa, Loteprednol Etabonate | $174 | $33,870147 claims |
| Harrow Eye, LLCVevye | $829 | $30,09235 claims |
| NovartisIlevro | $41 | $27,86574 claims |
| Kala Pharmaceuticals, Inc.Inveltys, Eysuvis | $410 | $21,36859 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 481 ophthalmology providers in Georgia.
Other ophthalmology in Marietta
- Robert StoltzMarietta$54K
- Annal MelethMarietta$34K
- Hersh ChopraMarietta$16K
- Gagan SawhneyAtlanta$582K
- Lawrence WoodardAtlanta$578K
- Stephanie VanderveldtAtlanta$384K
- Steven YehAtlanta$289K
- Jack ChapmanGainesville$244K
- Gregory LeeCumming$214K
- Jeffrey TranSuwanee$150K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.